Lecanemab: Difference between revisions
From Pharmacopedia
More actions
| [pending revision] | [pending revision] |
Expand Lecanemab with Stahl-sourced detail (with skepticism) |
MDElliottMD (talk | contribs) Tier 1 taxonomy consolidation: removed redundant Category:Anti-dementia (canonical already present); removed redundant Category:Anti-Amyloid Antibodies (canonical already present) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 8: | Line 8: | ||
| fda_max = 10 mg/kg q2w | | fda_max = 10 mg/kg q2w | ||
| routes = IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting | | routes = IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting | ||
| onset = Slowing of cognitive decline over 18 months (modest effect | | onset = Slowing of cognitive decline over 18 months (modest effect, ~27% relative slowing) | ||
| duration = Ongoing dosing | | duration = Ongoing dosing | ||
| halflife = ~5-7 days | | halflife = ~5-7 days | ||
| Line 16: | Line 16: | ||
| intro = '''Lecanemab''' (brand name Leqembi) is a humanized monoclonal antibody targeting soluble Aβ protofibrils, FDA-approved for Alzheimer disease (MCI/mild AD) via accelerated approval in January 2023 and converted to traditional approval in July 2023. Unlike aducanumab, lecanemab's pivotal trial (Clarity AD, 1795 patients, 18 months) was clearly positive: ~27% relative slowing of cognitive decline on CDR-SB. | | intro = '''Lecanemab''' (brand name Leqembi) is a humanized monoclonal antibody targeting soluble Aβ protofibrils, FDA-approved for Alzheimer disease (MCI/mild AD) via accelerated approval in January 2023 and converted to traditional approval in July 2023. Unlike aducanumab, lecanemab's pivotal trial (Clarity AD, 1795 patients, 18 months) was clearly positive: ~27% relative slowing of cognitive decline on CDR-SB. | ||
The effect is real but modest, and comes with substantial cost (~$26,500/year), inconvenience (biweekly IV infusions), and ARIA risk (especially in APOE ε4 homozygotes | The effect is real but modest, and comes with substantial cost (~$26,500/year), inconvenience (biweekly IV infusions), and ARIA risk (especially in APOE ε4 homozygotes, boxed warning recommends genotyping before treatment). Several deaths from ARIA-related cerebral edema/hemorrhage have been reported, particularly in patients on concurrent anticoagulants. | ||
The broader question of whether lecanemab's modest clinical benefit justifies the cost, risk, and burden is actively debated. Reasonable observers disagree. | The broader question of whether lecanemab's modest clinical benefit justifies the cost, risk, and burden is actively debated. Reasonable observers disagree. | ||
| pharmacodynamics= Humanized IgG1 with high affinity for Aβ protofibrils (and lower affinity for monomers and plaques). Promotes microglial Aβ clearance via Fc-receptor engagement. | | pharmacodynamics= Humanized IgG1 with high affinity for Aβ protofibrils (and lower affinity for monomers and plaques). Promotes microglial Aβ clearance via Fc-receptor engagement. | ||
| effects = '''ARIA-E''' (vasogenic edema) and '''ARIA-H''' (microhemorrhages) | | effects = '''ARIA-E''' (vasogenic edema) and '''ARIA-H''' (microhemorrhages), both often asymptomatic but can be serious. Infusion reactions. Headache. Boxed warning: APOE ε4 homozygotes at higher ARIA risk (~33% vs ~13% in non-carriers); genotype testing recommended before initiating. | ||
| interactions = <pharmaInteractions/> | | interactions = <pharmaInteractions/> | ||
}} | }} | ||
[[Category:Anti-Dementia Medicines]] | [[Category:Anti-Dementia Medicines]] | ||
[[Category:Anti-Amyloid Monoclonal Antibodies]] | [[Category:Anti-Amyloid Monoclonal Antibodies]] | ||
[[Category:Alzheimer Disease Medicines]] | [[Category:Alzheimer Disease Medicines]] | ||